Diagnostics and research stocks with the fastest expected revenue growth

Ranked

11

of 74 diagnostics and research stocks we cover

Median

+6.7%

Highest

+48.3%

WAT

Range

+4.7% to +48.3%

#	Company	Expected growth	Revenue growth (TTM)	Forward PE	Market cap
1	WATWaters	+48.3%	+52.5%	29.2×	$44.6B
2	GHGuardant Health	+31.1%	+42.7%	n/m	$22.7B
3	NTRANatera	+15.6%	+37.8%	n/m	$58.2B
4	DHRDanaher	+9.8%	+4.6%	25.4×	$162B
5	IDXXIDEXX Laboratories	+7.6%	+12.8%	35.9×	$44.1B
6	AAgilent Technologies	+6.7%	+8.6%	26.4×	$48.8B
7	ILMNIllumina	+5.6%	+4.9%	47.2×	$40.7B
8	IQVIQVIA	+5.5%	+8.2%	20.5×	$46B
9	LHLabcorp	+5.2%	+6.4%	17.4×	$26.7B
10	TMOThermo Fisher Scientific	+5.0%	+8.3%	25.0×	$249.1B
11	MTDMettler-Toledo International	+4.7%	+6.9%	33.9×	$33.5B

Not ranked: 60 with not a meaningful number. 3 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.